Pharma News, 2024

Smartwatches can detect symptoms of Parkinson’s and give scientists a better understanding of how to treat the disease, according to a new study.

Bristol Myers Squibb’s Augtyro (repotrectinib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat neurotrophic tyrosine receptor kinase (...

AbbVie and FutureGen Biopharmaceutical have announced a licence agreement worth $1.7bn to develop a pre-clinical therapy for inflammatory bowel disease (IBD).

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca‘s Farxiga (dapagliflozin) for the treatment of paediatric patients aged 10 years and above with type-2 ...

Since its inception in 2022, Santa Ana has progressed three programmes, with clinical trials expected to begin in 2025.

German science and technology company Merck KGaA has announced a €62m ($66.6m) investment to construct a new quality control facility for its Life Science business at its Darmstadt headquart...

Researchers from the Francis Crick Institute, University College London (UCL) and Imperial College London have identified a new major cause of inflammatory bowel disease (IBD).

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).

GC Biopharma is currently preparing clinical trials to evaluate the safety and tolerability of Sanfilippo Syndrome Type A treatment, “GC1130A” in South Korea, the United States, and Japan.

A third person has tested positive for avian influenza (flu, HPAI) H5N1 virus in the United States.

Over 65 million people around the globe are affected by epilepsy, a neurological disorder that impacts the nervous system and causes seizures.

Clinical trials testing either tominersen, an experimental therapy designed to target the underlying cause of Huntington’s disease, or dalzanemdor, an oral candidate that aims to improve cognitive a...